Mayne Pharma Group Overview

  • Year Founded
  • 1845

Year Founded

  • Status
  • Public

  • Employees
  • 160

Employees

  • Stock Symbol
  • MYX

Stock Symbol

  • Investments
  • 17

  • Share Price
  • $3.64
  • (As of Monday Closing)

Mayne Pharma Group General Information

Description

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.

Contact Information

Formerly Known As
Halcygen Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 1538 Main North Road
  • Salisbury, South Australia 5106
  • Australia
+61 (08)
Primary Industry
Drug Discovery
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • 1538 Main North Road
  • Salisbury, South Australia 5106
  • Australia
+61 (08)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mayne Pharma Group Stock Performance

As of 10-Feb-2025, Mayne Pharma Group’s stock price is $3.64. Its current market cap is $296M with 81.2M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.64 $2.94 $2.44 - $4.92 $296M 81.2M 149K -$1.44

Mayne Pharma Group Financials Summary

As of 30-Jun-2024, Mayne Pharma Group has a trailing 12-month revenue of $254M.

In Thousands,
USD
TTM 30-Jun-2024 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 185,923 185,923 128,693 516,311
Revenue 254,208 254,208 122,617 307,196
EBITDA (100,498) (100,498) (160,523) (120,259)
Net Income (114,182) (114,182) 78,824 (190,835)
Total Assets 764,100 764,100 825,663 885,976
Total Debt 25,948 25,948 31,445 284,565
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mayne Pharma Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mayne Pharma Group‘s full profile, request access.

Request a free trial

Mayne Pharma Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceutical
Drug Discovery
Salisbury, Australia
160 As of 2012

Mumbai, India
 

Woodcliff Lake, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mayne Pharma Group Competitors (16)

One of Mayne Pharma Group’s 16 competitors is Cipla, a Corporation company based in Mumbai, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cipla Corporation Mumbai, India
Par Pharmaceutical Companies Formerly PE-Backed Woodcliff Lake, NJ
Jubilant Pharmova Corporation Noida, India
Novartis Corporation Basel, Switzerland
GSK Corporation Middlesex, United Kingdom
You’re viewing 5 of 16 competitors. Get the full list »

Mayne Pharma Group Patents

Mayne Pharma Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180140614-A1 Corticosteriod containing foam compositions Inactive 15-Dec-2015
US-20190365783-A1 Halobetasol foam composition and method of manufacture thereof Inactive 15-Dec-2015
US-20180140615-A1 Method of manufacturing corticosteriod containing foam compositions Inactive 15-Dec-2015
AU-2016372790-A1 Corticosteroid containing foam compositions and method of manufacture thereof Inactive 15-Dec-2015
US-10857159-B2 Halobetasol foam composition and method of use thereof Active 15-Dec-2015 A61K9/122
To view Mayne Pharma Group’s complete patent history, request access »

Mayne Pharma Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mayne Pharma Group Investments & Acquisitions (17)

Mayne Pharma Group’s most recent deal was a Corporate Asset Purchase with EPI Health (Global Rights to the Rosacea Treatment RHOFADE) for . The deal was made on 26-Feb-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EPI Health (Global Rights to the Rosacea Treatment RHOFADE) 26-Feb-2024 Corporate Asset Purchase Buildings and Property
TherapeuticsMD ( Women's Healthcare products) 03-Jan-2023 Corporate Asset Purchase Buildings and Property
Mayne Pharma Group (US & Australian Rights to Halobetasol Foam & Related Assets) 26-Oct-2018 Corporate Asset Purchase Buildings and Property
INHIBITOR Therapeutics 11-Jan-2018 PIPE Pharmaceuticals
Glaxosmithkline (Dermatology foam assets and plaque psoriasis treatment Sorilux (calcipotriene)) 18-Aug-2016 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 17 investments and acquisitions. Get the full list »

Mayne Pharma Group ESG

Risk Overview

Risk Rating

Updated August, 10, 2024

27.34 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view Mayne Pharma Group’s complete esg history, request access »

Mayne Pharma Group Exits (4)

Mayne Pharma Group’s most recent exit was on 02-Aug-2016 from Teva Pharmaceuticals (US Generic Products Portfolio). The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Teva Pharmaceuticals (US Generic Products Portfolio) 02-Aug-2016 Completed
Metrics Contract Services 15-Nov-2012 Completed
PH&T 24-Jun-2005 Completed
Wasserburger Arzneimittelwerk 01-May-2004 Merger/Acquisition Completed
To view Mayne Pharma Group’s complete exits history, request access »

Mayne Pharma Group FAQs

  • When was Mayne Pharma Group founded?

    Mayne Pharma Group was founded in 1845.

  • Where is Mayne Pharma Group headquartered?

    Mayne Pharma Group is headquartered in Salisbury, Australia.

  • What is the size of Mayne Pharma Group?

    Mayne Pharma Group has 160 total employees.

  • What industry is Mayne Pharma Group in?

    Mayne Pharma Group’s primary industry is Drug Discovery.

  • Is Mayne Pharma Group a private or public company?

    Mayne Pharma Group is a Public company.

  • What is Mayne Pharma Group’s stock symbol?

    The ticker symbol for Mayne Pharma Group is MYX.

  • What is the current stock price of Mayne Pharma Group?

    As of 10-Feb-2025 the stock price of Mayne Pharma Group is $3.64.

  • What is the current market cap of Mayne Pharma Group?

    The current market capitalization of Mayne Pharma Group is $296M.

  • What is Mayne Pharma Group’s current revenue?

    The trailing twelve month revenue for Mayne Pharma Group is $254M.

  • Who are Mayne Pharma Group’s competitors?

    Cipla, Par Pharmaceutical Companies, Jubilant Pharmova, Novartis, and GSK are some of the 16 competitors of Mayne Pharma Group.

  • What is Mayne Pharma Group’s annual earnings per share (EPS)?

    Mayne Pharma Group’s EPS for 12 months was -$1.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »